FDA Rejects Soligenix's Lymphoma Candidate

The FDA has rejected Soligenix's New Drug Application for HyBryte (synthetic hypericin), a therapeutic developed to treat early-stage cutaneous T-cell lymphoma (CTCL), the company announced Tuesday.